SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE

SAN DIEGO, CA, Aug. 8, 2008 Senomyx, Inc.(Nasdaq: SNMX), a leading company focused on using proprietary taste receptortechnologies to discover and develop novel flavor ingredients for the food,beverage, and ingredient supply industries, announced today that Kent Snyder,the Company's President and CEO, and Mark Zoller, Ph.D., Executive VicePresident of Discovery & Development and CSO, will present a corporateoverview on Thursday, August 14, at 2:00 p.m. Eastern Time (11:00 a.m. PacificTime) during the Canaccord Adams 28th Annual Global Growth Conference. Theconference is taking place at the Intercontinental Hotel in Boston. Thepresenters will discuss corporate developments and the Company's pipeline ofnovel flavor ingredients.

To access the live presentation or a subsequent archived recording, pleaselog onto Senomyx's website at http://www.senomyx.com and click on the"Investor Relations" tab. The archived webcast will be available for 30 daysfollowing the presentation. Please connect to Senomyx's website prior to thestart of the webcast to ensure adequate time to download any software that maybe necessary.

About Senomyx, Inc. (http://www.senomyx.com)

Senomyx is a leading company using proprietary taste receptor technologiesto discover and develop novel flavor ingredients in the savory, sweet, salt,bitter, and cooling areas. Senomyx has entered into product discovery anddevelopment collaborations with seven of the world's foremost food, beverage,and ingredient supply companies: Ajinomoto Co., Inc., Cadbury plc, CampbellSoup Company, The Coca-Cola Company, Firmenich SA, Nestle SA, and Solae.Nestle is currently marketing products that contain one of Senomyx's flavoringredients. For more information, please visit http://www.senomyx.comContact: Gwen Rosenberg Senomyx, Inc. Vice President, Investor Relations & Corporate Communications 858-646-8369 [email protected]

SOURCE Senomyx, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...